PHILADELPHIA, PA — Proscia has been named to KLAS Research’s 2024 Emerging Solutions Top 20 list, highlighting technologies poised to advance the Quadruple Aim of Healthcare. This accolade underscores the impact of Proscia’s Concentriq® software, which has been lauded by healthcare leaders nationwide for its role in enhancing patient outcomes.
The announcement was made at the HLTH USA event in Las Vegas, where Proscia was celebrated among other innovators. Adam Gale, CEO of KLAS, praised the winners for their market disruption, stating, “The 2024 Emerging Solutions Top 20 winners are truly disrupting the market with their innovative solutions. These companies are demonstrating exceptional creativity and effectiveness in taking on some of healthcare’s biggest challenges. We are excited to see how these solutions will continue to evolve and impact the healthcare industry.”
KLAS evaluated a wide range of emerging solutions, selecting those that scored 85 or higher in evaluations using their proprietary methodology. The rankings reflect the potential of these technologies to improve healthcare outcomes, reduce costs, and enhance both patient and clinician experiences.
Proscia’s Concentriq platform stands out for addressing the pressing challenges faced by laboratories worldwide, including the rising diagnostic burden and a shortage of pathologists. By digitizing labs and enabling AI applications, Concentriq helps deliver faster and more efficient pathology results. Eder Lagemann, KLAS Research Director, noted, “Labs worldwide feel the impact of rising diagnostic burden and a shortage of pathologists. To help ease this burden, Proscia offers Concentriq, an enterprise pathology platform that allows organizations to digitize their labs and adopt AI applications that help deliver more efficient results.”
The customer feedback gathered by KLAS indicates that all surveyed users of Concentriq reported achieving significant outcomes within six months of implementation. Improvements in turnaround times, talent acquisition, and the establishment of a robust data archive for research were among the benefits cited. Additionally, 100% of customers expressed their willingness to continue using Concentriq, praising the platform’s support and Proscia’s expertise in pathology.
David West, CEO of Proscia, shared his enthusiasm about the recognition, stating, “We are rewiring pathology with software and AI to fuel the fight against humanity’s most challenging diseases, like cancer. KLAS’ recognition underscores our commitment to giving pathologists the great software they deserve to benefit them and their patients.”
This recognition positions Proscia and its Concentriq platform at the forefront of healthcare innovation, setting a new standard for excellence in digital pathology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.